J&J Will Extend Neuro Presence With $480 Million Micrus Acquisition
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson's $480 million acquisition of Micrus Endovascular will expand its presence in the hemorrhagic stroke market and give the company a foothold in the high-promise ischemic stroke space
You may also be interested in...
Intracranial Stenting Doesn’t Make The Cut In NIH Study
Intracranial stenting should not be a first-line treatment in most patients with narrowed brain arteries and a recent neurological event, researchers concluded in a recent study. But the data should not be viewed as a nail in the coffin to future development of intracranial stents, investigators stressed.
Intracranial Stenting Doesn't Make The Cut In NIH Study
The findings suggest that medical therapy alone may be better than combining it with brain stenting for preventing recurrent strokes in high-risk populations, researchers say.
Intracranial Stenting Doesn’t Make The Cut In NIH Study
Intracranial stenting should not be a first-line treatment in most patients with narrowed brain arteries and a recent neurological event, researchers concluded in a recent study. But the data should not be viewed as a nail in the coffin to future development of intracranial stents, investigators stressed.